Page 50 - Medication Guide News Today : Breaking News, Live

UCB Announces FINTEPLA® (fenfluramine) Oral Solution Is Now Descheduled and Is No Longer Listed as a Controlled Substance

Published: April 17, 2023

/PRNewswire/ -- UCB (Euronext: UCB), a global biopharmaceutical company, today announced the U.S. Drug Enforcement Administration (DEA) has published a final...

Source: prnewswire.com

FDA Updates Opioid Analgesic Labeling to Help Guide Prescribing Decisions

Published: April 17, 2023

The FDA has updated the prescribing information for all opioid analgesics in order to provide additional guidance on how to safely prescribe these medications.

Source: psychiatryadvisor.com

IMFINZI-based treatment before and after surgery reduced the risk of disease recurrence, progression events or death by 32% in resectable non-small cell lung cancer in the AEGEAN Phase III trial

Published: April 16, 2023

Results presented at AACR 2023 found that four times as many patients treated with Imfinzi plus chemotherapy before surgery achieved pathologic complete response versus those treated with neoadjuvant... | April 16, 2023

Source: marketscreener.com

Merck's KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival Compared to Chemotherapy Alone in Patients With Advanced or Unresectable Biliary Tract Cancer | Business

Published: April 16, 2023

RAHWAY, N.J.--(BUSINESS WIRE)--Apr 16, 2023--

Source: cadillacnews.com

$MorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL Patients Treated with Monjuvi® (tafasitamab-cxix) - Vimarsana News$

MorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL Patients Treated with Monjuvi® (tafasitamab-cxix)

Published: April 16, 2023

EQS-News: MorphoSys AG / Key word: Miscellaneous MorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL... | April 16, 2023

Source: marketscreener.com

Page 50 - Medication Guide News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Top News In Medication Guide Today - Breaking & Trending Today

UCB Announces FINTEPLA® (fenfluramine) Oral Solution Is Now Descheduled and Is No Longer Listed as a Controlled Substance

FDA Updates Opioid Analgesic Labeling to Help Guide Prescribing Decisions

IMFINZI-based treatment before and after surgery reduced the risk of disease recurrence, progression events or death by 32% in resectable non-small cell lung cancer in the AEGEAN Phase III trial

Merck's KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival Compared to Chemotherapy Alone in Patients With Advanced or Unresectable Biliary Tract Cancer | Business

MorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL Patients Treated with Monjuvi® (tafasitamab-cxix)

Page 50 - Medication Guide News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Top News In Medication Guide Today - Breaking & Trending Today

UCB Announces FINTEPLA&#xAE; (fenfluramine) Oral Solution Is Now Descheduled and Is No Longer Listed as a Controlled Substance

FDA Updates Opioid Analgesic Labeling to Help Guide Prescribing Decisions

IMFINZI-based treatment before and after surgery reduced the risk of disease recurrence, progression events or death by 32% in resectable non-small cell lung cancer in the AEGEAN Phase III trial

Merck's KEYTRUDA&#xAE; (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival Compared to Chemotherapy Alone in Patients With Advanced or Unresectable Biliary Tract Cancer | Business

MorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL Patients Treated with Monjuvi&#xAE; (tafasitamab-cxix)

UCB Announces FINTEPLA® (fenfluramine) Oral Solution Is Now Descheduled and Is No Longer Listed as a Controlled Substance

Merck's KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival Compared to Chemotherapy Alone in Patients With Advanced or Unresectable Biliary Tract Cancer | Business

MorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL Patients Treated with Monjuvi® (tafasitamab-cxix)